Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: April 29, 2025
Antiviral Peptide + Nonhormonal Contraceptive IVR
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Oak Crest Institute of Science
Active
Last updated: April 29, 2025
Injectable Porous Silicon Microparticles
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of California San Diego, FHI 360
Active
Last updated: April 17, 2025
Herbal Bioactive Spermicide
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Lagos
Active
Last updated: April 17, 2025
DMPA SI

TV-46046

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Teva, FHI 360
Active
Last updated: April 9, 2025
Trimegestone Ring

TMG + Estriol Ring

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Short-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Evestra, Dinox, University of Campinas (UNICAMP), SocraTec R&D GmbH
Active
Last updated: April 9, 2025
Self-Aggregating Injectable Microcrystals
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Not Yet Determined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Massachusetts Institute of Technology
Active
Last updated: April 9, 2025
PPGSU EFdA LNG Implant
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Long-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Secant Group
Active
Last updated: April 9, 2025
Oui

Chitosan Vaginal Tablets

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Pericoital
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Cirqle Biomedical, Organon
Active
Last updated: April 9, 2025
Once-a-Month Oral Contraceptive

Levonorgestrel Gastric Resident Dosage Form, Levonorgestrel Gastric Retentive Dosage Form

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Lyndra Therapeutics, Massachusetts Institute of Technology